89bio Competitors

Revance Therapeutics (NASDAQ:RVNC) and 89bio (NASDAQ:ETNB) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, dividends, risk, analyst recommendations, institutional ownership, valuation and earnings.

Institutional & Insider Ownership

74.4% of Revance Therapeutics shares are held by institutional investors. Comparatively, 80.6% of 89bio shares are held by institutional investors. 4.8% of Revance Therapeutics shares are held by insiders. Comparatively, 18.1% of 89bio shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Revance Therapeutics and 89bio's net margins, return on equity and return on assets.

Earnings and Valuation

This table compares Revance Therapeutics and 89bio's revenue, earnings per share and valuation.

89bio has lower revenue, but higher earnings than Revance Therapeutics. Revance Therapeutics is trading at a lower price-to-earnings ratio than 89bio, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Revance Therapeutics and 89bio, as reported by MarketBeat.

Revance Therapeutics currently has a consensus price target of $36.40, suggesting a potential upside of 29.40%. 89bio has a consensus price target of $62.4286, suggesting a potential upside of 137.55%. Given 89bio's stronger consensus rating and higher probable upside, analysts clearly believe 89bio is more favorable than Revance Therapeutics.

Summary

89bio beats Revance Therapeutics on 10 of the 13 factors compared between the two stocks.

Dicerna Pharmaceuticals (NASDAQ:DRNA) and 89bio (NASDAQ:ETNB) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, dividends, risk, analyst recommendations, institutional ownership, valuation and earnings.

Institutional & Insider Ownership

80.6% of Dicerna Pharmaceuticals shares are held by institutional investors. Comparatively, 80.6% of 89bio shares are held by institutional investors. 11.3% of Dicerna Pharmaceuticals shares are held by insiders. Comparatively, 18.1% of 89bio shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Dicerna Pharmaceuticals and 89bio's net margins, return on equity and return on assets.

Earnings and Valuation

This table compares Dicerna Pharmaceuticals and 89bio's revenue, earnings per share and valuation.

89bio has lower revenue, but higher earnings than Dicerna Pharmaceuticals. Dicerna Pharmaceuticals is trading at a lower price-to-earnings ratio than 89bio, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Dicerna Pharmaceuticals and 89bio, as reported by MarketBeat.

Dicerna Pharmaceuticals currently has a consensus price target of $37.8333, suggesting a potential upside of 45.01%. 89bio has a consensus price target of $62.4286, suggesting a potential upside of 137.55%. Given 89bio's stronger consensus rating and higher probable upside, analysts clearly believe 89bio is more favorable than Dicerna Pharmaceuticals.

Summary

89bio beats Dicerna Pharmaceuticals on 8 of the 12 factors compared between the two stocks.

Axsome Therapeutics (NASDAQ:AXSM) and 89bio (NASDAQ:ETNB) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, dividends, risk, analyst recommendations, institutional ownership, valuation and earnings.

Profitability

This table compares Axsome Therapeutics and 89bio's net margins, return on equity and return on assets.

Institutional & Insider Ownership

63.6% of Axsome Therapeutics shares are held by institutional investors. Comparatively, 80.6% of 89bio shares are held by institutional investors. 26.0% of Axsome Therapeutics shares are held by insiders. Comparatively, 18.1% of 89bio shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Axsome Therapeutics and 89bio, as reported by MarketBeat.

Axsome Therapeutics currently has a consensus price target of $146.90, suggesting a potential upside of 177.22%. 89bio has a consensus price target of $62.4286, suggesting a potential upside of 137.55%. Given Axsome Therapeutics' higher probable upside, analysts clearly believe Axsome Therapeutics is more favorable than 89bio.

Earnings and Valuation

This table compares Axsome Therapeutics and 89bio's revenue, earnings per share and valuation.

Axsome Therapeutics is trading at a lower price-to-earnings ratio than 89bio, indicating that it is currently the more affordable of the two stocks.

Summary

89bio beats Axsome Therapeutics on 7 of the 11 factors compared between the two stocks.

89bio (NASDAQ:ETNB) and NGM Biopharmaceuticals (NASDAQ:NGM) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, valuation, institutional ownership, risk, profitability, analyst recommendations and dividends.

Profitability

This table compares 89bio and NGM Biopharmaceuticals' net margins, return on equity and return on assets.

Insider and Institutional Ownership

80.6% of 89bio shares are held by institutional investors. Comparatively, 49.6% of NGM Biopharmaceuticals shares are held by institutional investors. 18.1% of 89bio shares are held by company insiders. Comparatively, 50.4% of NGM Biopharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a summary of current ratings and target prices for 89bio and NGM Biopharmaceuticals, as provided by MarketBeat.

89bio presently has a consensus target price of $62.4286, suggesting a potential upside of 137.55%. NGM Biopharmaceuticals has a consensus target price of $39.1111, suggesting a potential upside of 53.80%. Given 89bio's higher possible upside, equities research analysts clearly believe 89bio is more favorable than NGM Biopharmaceuticals.

Valuation & Earnings

This table compares 89bio and NGM Biopharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.

NGM Biopharmaceuticals has higher revenue and earnings than 89bio. NGM Biopharmaceuticals is trading at a lower price-to-earnings ratio than 89bio, indicating that it is currently the more affordable of the two stocks.

Summary

NGM Biopharmaceuticals beats 89bio on 8 of the 13 factors compared between the two stocks.

89bio (NASDAQ:ETNB) and Morphic (NASDAQ:MORF) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, valuation, institutional ownership, risk, profitability, analyst recommendations and dividends.

Profitability

This table compares 89bio and Morphic's net margins, return on equity and return on assets.

Insider and Institutional Ownership

80.6% of 89bio shares are held by institutional investors. Comparatively, 61.5% of Morphic shares are held by institutional investors. 18.1% of 89bio shares are held by company insiders. Comparatively, 39.5% of Morphic shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a summary of current ratings and target prices for 89bio and Morphic, as provided by MarketBeat.

89bio presently has a consensus target price of $62.4286, suggesting a potential upside of 137.55%. Morphic has a consensus target price of $63.3333, suggesting a potential upside of 6.71%. Given 89bio's stronger consensus rating and higher possible upside, equities research analysts clearly believe 89bio is more favorable than Morphic.

Valuation & Earnings

This table compares 89bio and Morphic's top-line revenue, earnings per share (EPS) and valuation.

Morphic has higher revenue and earnings than 89bio. Morphic is trading at a lower price-to-earnings ratio than 89bio, indicating that it is currently the more affordable of the two stocks.

89bio (NASDAQ:ETNB) and Kura Oncology (NASDAQ:KURA) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, valuation, institutional ownership, risk, profitability, analyst recommendations and dividends.

Profitability

This table compares 89bio and Kura Oncology's net margins, return on equity and return on assets.

Insider and Institutional Ownership

80.6% of 89bio shares are held by institutional investors. Comparatively, 94.7% of Kura Oncology shares are held by institutional investors. 18.1% of 89bio shares are held by company insiders. Comparatively, 11.0% of Kura Oncology shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a summary of current ratings and target prices for 89bio and Kura Oncology, as provided by MarketBeat.

89bio presently has a consensus target price of $62.4286, suggesting a potential upside of 137.55%. Kura Oncology has a consensus target price of $39.5455, suggesting a potential upside of 38.42%. Given 89bio's stronger consensus rating and higher possible upside, equities research analysts clearly believe 89bio is more favorable than Kura Oncology.

Valuation & Earnings

This table compares 89bio and Kura Oncology's top-line revenue, earnings per share (EPS) and valuation.

Kura Oncology is trading at a lower price-to-earnings ratio than 89bio, indicating that it is currently the more affordable of the two stocks.

Summary

89bio beats Kura Oncology on 6 of the 11 factors compared between the two stocks.